The US Food and Drug Administration has approved Ocrevus (ocrelizumab) in multiple sclerosis. It is the first drug that gets approval for both relapsing remitting and primary progressive form of the disease.
Ocrelizumab showed positive results in three phase III trials (Opera I, Opera II & ORATORIO).
Read the official announcement here
